Avalo Therapeutics (AVTX) Non Operating Income (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Non Operating Income data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Non Operating Income rose 11.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 104.09% YoY) and the FY2025 annual result came in at -$5.2 million, down 115.43% from the prior year.
• Non Operating Income advanced to $1.3 million in Q1 2026, from -$8.5 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $108.0 million in Q2 2024 to a low of -$21.9 million in Q4 2024.
• A 5-year average of $6.5 million and a median of -$898000.0 in 2022 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income tumbled 7094.12% — and 2024, when it soared 10529.05%.
• Tracing AVTX's Non Operating Income over 5 years: stood at -$949000.0 in 2022, then surged by 45.31% to -$519000.0 in 2023, then slumped by 4122.35% to -$21.9 million in 2024, then jumped by 61.05% to -$8.5 million in 2025, then jumped by 115.03% to $1.3 million in 2026.
• The last three Non Operating Income figures came in at $1.3 million (Q1 2026), -$8.5 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.